ORPHELIA Pharma

📍 Paris, France🗓 Founded 2007👥 8 employees💰 Last funded Oct 2017
Pharmaceutical Manufacturing🌐 orphelia-pharma.eu
Website LinkedIn
ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus on developing optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. We are also leading R&D projects aiming at developing new drugs for pediatric orphan or ultra-rare indications. ORPHELIA’s portfolio encompasses drugs for the treatment of West Syndrome (epilepsy), relapsed or refractory high-risk neuroblastoma and acute lymphoblastic leukemia, with a first marketing authorization expected in 2018. ORPHELIA is headquartered in Paris with a secondary site in Lyon area. Key investors include initiative Octalfa (lead investor) and Pierre Fabre Medicament.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
2007
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
2
Frequently asked questions
Who invested in ORPHELIA Pharma?
ORPHELIA Pharma has 2 investors on record on gritt.io and 1 late-stage investors.
When did ORPHELIA Pharma last raise funding?
The most recent investment in ORPHELIA Pharma recorded on gritt.io was in October 2017.
When was ORPHELIA Pharma founded?
ORPHELIA Pharma was founded in 2007.
What industry is ORPHELIA Pharma in?
ORPHELIA Pharma operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is ORPHELIA Pharma based?
ORPHELIA Pharma is headquartered in Paris, France.